Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET) [PDF]
, 2005 Giovanni Barosi
openalex +1 more source
Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study [PDF]
, 2020 Vikas Gupta +13 more
openalex +1 more source
Low-Dose Splenic Irradiation in Myelofibrosis—A Safe Adjunct to Hematopoietic Cell Transplantation [PDF]
, 2016 Noah S. Kalman +7 more
openalex +1 more source
Pulmonary arterial hypertension exacerbated by ruxolitinib [PDF]
, 2015 Harrison, C +3 more
core +2 more sources
MESENCHYMAL STEM CELLS IN PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS: IDLE OBSERVERS OR PART OF THE DISEASE? [PDF]
, 2019 Accurso, V. +8 more
core +1 more source
Retroperitoneal extramedullary hematopoietic pseudotumor in ataxia-telangiectasia. [PDF]
, 2018 Ataxia-telangiectasia confers a significant increase in the development of several cancer types, most commonly leukemia and lymphoma. However, as the natural history for these patients is evolving and their lifespan is increasing, there is the potential ...
Bateni, Cyrus P +5 more
core
Prevalence of pulmonary hypertension in myelofibrosis
, 2020 Juan Lopez‐Mattei +11 more
openalex +2 more sources
Profile of pomalidomide and its potential in the treatment of myelofibrosis
Therapeutics and Clinical Risk Management, 2015 Krisstina L Gowin, Ruben A Mesa Division of Hematology and Medical Oncology, Mayo Clinic Arizona, Scottsdale, AZ, USA Abstract: Myelofibrosis, a Philadelphia-negative myeloproliferative neoplasm, is in a new treatment era after the discovery of ...
Gowin KL, Mesa RA
doaj